Request Demo
Last update 02 Nov 2025
Flavoxate Hydrochloride
Last update 02 Nov 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms 2-(1-piperidinyl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate, 2-piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate, 2-piperidinoethyl 3-methylflavone-8-carboxylate + [20] |
Target |
Action inhibitors |
Mechanism ORAI1 inhibitors(Calcium release-activated calcium channel protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (15 Jan 1970), |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC24H26ClNO4 |
InChIKeyXOEVKNFZUQEERE-UHFFFAOYSA-N |
CAS Registry3717-88-2 |
Related
5
Clinical Trials associated with Flavoxate HydrochlorideCTRI/2024/09/073950
Effect of oral flavoxate on postoperative catheter related bladder dysfunction in adult males undergoing transurethral resection of bladder tumors- A randomized controlled trial vs solifenacin and placebo - Nil
CTRI/2020/04/024700
Single dose oral bioavailability pilot study of two test formulations ofFlavoxate XR Tablet 600 mg, once a day (T1) and Flavoxate XR Tablet800 mg, once a day (T2) and reference formulation of Flavoxate Tablet200 mg, thrice a day (R) in healthy adult male subjects under fastingconditions.
JPRN-UMIN000009999
Clinical evaluation of add-on administration of flavoxate hydrochloride in nocturia patients resistant to an anticholinergic agent - Clinical evaluation of add-on administration of flavoxate hydrochloride in nocturia patients
100 Clinical Results associated with Flavoxate Hydrochloride
Login to view more data
100 Translational Medicine associated with Flavoxate Hydrochloride
Login to view more data
100 Patents (Medical) associated with Flavoxate Hydrochloride
Login to view more data
280
Literatures (Medical) associated with Flavoxate Hydrochloride09 Sep 2025CHEMICAL RECORD
Harnessing Chromone as a Versatile Scaffold for Emerging Biological Applications: Recent Advances and Medicinal Insights.
Review
Author: Gogoi, Neelutpal ; Dutta, Debashis ; Kaishap, Partha Pratim ; Laskar, Boonam ; Dey, Tapan
Chromones, characterized by a benzo-annulated γ-pyrone core, represent a privileged scaffold, offering a diverse pharmacological spectrum. Clinically approved drugs such as disodium cromoglycate and flavoxate underscore their therapeutic significance. Recent advancements in synthetic strategies have facilitated the development of novel chromone derivatives with improved bioactivity, selectively modulating key molecular targets implicated in cancer, inflammation, diabetes, infectious diseases, and neurodegenerative disorders. Furthermore, their emerging utility as imaging probes and regulators of pharmacologically relevant targets, such as pyridoxal phosphatase (PDXP), highlights their expanding role in modern drug discovery. This review provides a comprehensive overview of recent progress in the identification of bioactive chromone-based natural products and synthetic analogs, emphasizing their therapeutic potential. Additionally, critical innovations in recent synthetic methodologies and targeted therapeutic applications are discussed, reinforcing chromones as a sustainable and multifunctional framework for next-generation drug development.
03 Jul 2025Expert Opinion On Drug Safety
Potentially inappropriate anticholinergic drug use among older adults in primary healthcare: prevalence and determinants
Article
Author: Figueiras, Adolfo ; Mateos-Campos, Ramona ; Herdeiro, Maria Teresa ; Rodrigues, Daniela A. ; Roque, Fátima
BACKGROUND:
Considering the vulnerability of older adults to adverse drug reactions, medications with strong anticholinergic properties are considered potentially inappropriate for this population. This study aims to characterize older adults' profile of anticholinergics use and to identify the factors associated with their potentially inappropriate use.
RESEARCH DESIGN AND METHODS:
A retrospective study was conducted on 1200 older adults in primary health care centers of Portugal between April 2021 and August 2022. Potentially inappropriate use was assessed according to the 2023 Beers criteria. Logistic regression analyses were performed to determine associations between independent variables and potentially inappropriate use.
RESULTS:
A 8.9% (95% CI 0.074-0.107) of the older adults were exposed to one or more potentially inappropriate anticholinergics, and amitriptyline was the most used (2.0%). Multivariate analysis revealed that use was associated with a higher mean number of medications (OR 1.173, 95% CI 1.115-1.234), diagnoses of depression (OR 2.889, 95% CI 1.785-4.674) and psychiatric disorders (OR 1.654, 95% CI 1.003-2.729).
CONCLUSIONS:
This study underscores the importance of vigilance in prescribing anticholinergic medications to older adults, particularly those with higher medication burdens and mental health diagnoses. By identifying factors associated with potentially inappropriate use, healthcare providers can better tailor medication regimens to mitigate risks and optimize the well-being of older adults.
01 Jun 2025BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
Both carvedilol and cimetidine alleviate cisplatin-induced nephrotoxicity via downregulating OCT2
Article
Author: Jiao, Xiaoyan ; Wu, Huan ; Ning, Yichun ; Sun, Zhaoxing ; Ji, Ji ; Yu, Xiaofang ; Ding, Xiaoqiang ; Cheng, Xin ; Xu, Xiaoliang ; Lu, Min
BACKGROUND:
Cisplatin is a common chemotherapy agent for solid tumors but severe nephrotoxicity limits its application, with no effective pharmacological treatments. Organic cation transporter 2 (OCT2) is involved in cisplatin uptake in kidneys. This study aimed to find drugs with promising clinical applications that could prevent cisplatin-induced acute kidney injury (Cis-AKI) by inhibiting OCT2.
METHODS:
The mRNA level of OCT2 was examined in human induced pluripotent stem cells (iPSCs) from Cis-AKI patients and paired non-AKI patients. The association between OCT2 and Cis-AKI was investigated by HEK293FT cells and kidney organoids. We screened potential compounds exhibiting protective effects against Cis-AKI in US Food and Drug Administration-approved drugs through virtual screening and activity screening. Subsequently, we determined the effects of these compounds on OCT2 expression, cisplatin uptake, and apoptosis in cells, kidney organoids and mice. A549 and HeLa cells were adopted to observe the influence of drugs on the anti-tumor function of cisplatin.
RESULTS:
Compared to non-AKI patients, the OCT2 mRNA levels of iPSCs from Cis-AKI patients were elevated. OCT2 exhibits similar expression patterns in kidney organoids and human kidney tissues. Furthermore, the overexpression of OCT2 in kidney organoids and HEK293FT cells exacerbated the injury caused by cisplatin. Carvedilol and cimetidine were identified as potent OCT2 inhibitors by drug screening. Further analysis revealed that the pretreatment of carvedilol or cimetidine downregulated OCT2, reduced cisplatin uptake, and alleviated cisplatin-induced apoptosis, but the combination of the two drugs didn't further improve these outcomes. Additionally, carvedilol and cimetidine didn't compromise the cisplatin-induced cell death in A549 and HeLa cells.
CONCLUSION:
Our study confirmed that carvedilol and cimetidine exert protective effects against Cis-AKI by inhibiting OCT2, without altering the anti-tumor effects of cisplatin.
1
News (Medical) associated with Flavoxate Hydrochloride
100 Deals associated with Flavoxate Hydrochloride
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D00718 | Flavoxate Hydrochloride |
R&D Status
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Urethral Diseases | China | 01 Jan 1995 | |
| Chronic prostatitis | Japan | 01 Aug 1978 | |
| Cystitis | Japan | 01 Aug 1978 | |
| Pollakisuria | Japan | 01 Aug 1978 | |
| Dysuria | United States | 15 Jan 1970 | |
| Pain | United States | 15 Jan 1970 | |
| Urinary Bladder, Overactive | United States | 15 Jan 1970 | |
| Urinary Incontinence | United States | 15 Jan 1970 | |
| Urinary Incontinence, Urge | United States | 15 Jan 1970 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free